JP5818440B2 - バイオマーカー - Google Patents

バイオマーカー Download PDF

Info

Publication number
JP5818440B2
JP5818440B2 JP2010550627A JP2010550627A JP5818440B2 JP 5818440 B2 JP5818440 B2 JP 5818440B2 JP 2010550627 A JP2010550627 A JP 2010550627A JP 2010550627 A JP2010550627 A JP 2010550627A JP 5818440 B2 JP5818440 B2 JP 5818440B2
Authority
JP
Japan
Prior art keywords
ins
fragment
antibody
antigen
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010550627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516037A (ja
JP2011516037A5 (enExample
Inventor
クリストファー ジョセフ ペンバートン，
クリストファー ジョセフ ペンバートン，
アーサー マーク リチャーズ，
アーサー マーク リチャーズ，
マイケル ゲイリー ニコールズ，
マイケル ゲイリー ニコールズ，
ティモシー グラント ヤンデル，
ティモシー グラント ヤンデル，
Original Assignee
オタゴ イノベーション リミテッド
オタゴ イノベーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オタゴ イノベーション リミテッド, オタゴ イノベーション リミテッド filed Critical オタゴ イノベーション リミテッド
Publication of JP2011516037A publication Critical patent/JP2011516037A/ja
Publication of JP2011516037A5 publication Critical patent/JP2011516037A5/ja
Application granted granted Critical
Publication of JP5818440B2 publication Critical patent/JP5818440B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010550627A 2008-03-12 2009-03-12 バイオマーカー Expired - Fee Related JP5818440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3577008P 2008-03-12 2008-03-12
US61/035,770 2008-03-12
PCT/NZ2009/000031 WO2009113879A1 (en) 2008-03-12 2009-03-12 Biomarkers

Publications (3)

Publication Number Publication Date
JP2011516037A JP2011516037A (ja) 2011-05-26
JP2011516037A5 JP2011516037A5 (enExample) 2012-06-07
JP5818440B2 true JP5818440B2 (ja) 2015-11-18

Family

ID=41065427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550627A Expired - Fee Related JP5818440B2 (ja) 2008-03-12 2009-03-12 バイオマーカー

Country Status (9)

Country Link
US (2) US9630985B2 (enExample)
EP (1) EP2265641B1 (enExample)
JP (1) JP5818440B2 (enExample)
CN (2) CN107043418A (enExample)
AU (1) AU2009224113B2 (enExample)
CA (1) CA2715914C (enExample)
DK (1) DK2265641T3 (enExample)
ES (1) ES2666725T3 (enExample)
WO (1) WO2009113879A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666725T3 (es) 2008-03-12 2018-05-07 Otago Innovation Limited Biomarcadores
US20140147874A1 (en) * 2011-03-04 2014-05-29 The Johns Hopkins University Biomarkers of cardiac ischemia
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
US11566304B2 (en) 2017-09-14 2023-01-31 Lixivia, Inc. Methods for recovering copper, cobalt, indium and nickel with amine containing lixiviant
MA52870A (fr) * 2018-06-13 2021-04-21 Acraf Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3
CN116199793B (zh) * 2023-03-13 2025-05-02 广州源博医药科技有限公司 一种长效重组犬胰岛素融合蛋白的制备方法及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5310687A (en) * 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU7568391A (en) * 1990-05-07 1991-11-27 Immunomedics Inc. Improved method for radiolabeling monovalent antibody fragments
WO1992005282A1 (en) * 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5221685A (en) 1991-02-01 1993-06-22 Ube Industries, Ltd. Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) * 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) * 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) * 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) * 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE242485T1 (de) * 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
PT653639E (pt) * 1993-11-12 2000-06-30 Unilever Nv Equipamentos analiticos e metodos para a sua utilizacao
ATE224053T1 (de) * 1993-11-12 2002-09-15 Inverness Medical Switzerland Vorrichtung zum ablesen von teststreifen
US5647124A (en) 1994-04-25 1997-07-15 Texas Instruments Incorporated Method of attachment of a semiconductor slotted lead to a substrate
GB9419267D0 (en) 1994-09-23 1994-11-09 Unilever Plc Assay devices
US5792294A (en) * 1995-11-16 1998-08-11 Otis Elevator Company Method of replacing sheave liner
US5719600A (en) 1995-12-12 1998-02-17 Hewlett-Packard Company Gradient calculation system and method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) * 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6600155B1 (en) * 1998-01-23 2003-07-29 Analytica Of Branford, Inc. Mass spectrometry from surfaces
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6831060B2 (en) * 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
CN1346680A (zh) * 2000-10-09 2002-05-01 北京大学 一种用于直接肌肉注射治疗糖尿病的人胰岛素前体基因和含有该基因的质粒
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
JP2005513479A (ja) * 2001-12-21 2005-05-12 センス プロテオミック リミテッド 質量分析用のプローブ
AUPS169202A0 (en) 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
US7045366B2 (en) * 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
JP2006527190A (ja) * 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
ZA200510282B (en) 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
NZ552667A (en) * 2004-07-23 2009-04-30 Inst Medical W & E Hall Therapeutic and diagnostic agents
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
JP2006292623A (ja) 2005-04-13 2006-10-26 Univ Of Dundee 心不全における突然死のマーカー
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
CA2662629C (en) * 2006-09-07 2019-08-13 University Of Otago Bnp signal peptide fragments for acute cardiac disorders
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
ES2666725T3 (es) 2008-03-12 2018-05-07 Otago Innovation Limited Biomarcadores
EP2265642A4 (en) * 2008-03-12 2012-05-02 Otago Innovation Ltd BIOMARKERS

Also Published As

Publication number Publication date
AU2009224113A1 (en) 2009-09-17
JP2011516037A (ja) 2011-05-26
CN102037014A (zh) 2011-04-27
DK2265641T3 (en) 2018-04-23
US9630985B2 (en) 2017-04-25
EP2265641A4 (en) 2012-08-01
US20180051050A1 (en) 2018-02-22
EP2265641B1 (en) 2018-01-24
CN107043418A (zh) 2017-08-15
US10106575B2 (en) 2018-10-23
CA2715914A1 (en) 2009-09-17
EP2265641A1 (en) 2010-12-29
WO2009113879A1 (en) 2009-09-17
AU2009224113B2 (en) 2013-02-21
ES2666725T3 (es) 2018-05-07
US20110104723A1 (en) 2011-05-05
CA2715914C (en) 2019-01-22

Similar Documents

Publication Publication Date Title
AU2009224114B2 (en) Biomarkers
US8298772B2 (en) Methods of diagnosing acute cardiac disorders using BNP-SP
US10106575B2 (en) Biomarkers
US20110033874A1 (en) Biomarkers

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120220

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120312

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140328

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150929

R150 Certificate of patent or registration of utility model

Ref document number: 5818440

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees